Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

6q Deletion Helps in the Discrimination Between Symptomatic Waldenström's Macroglobulinemia and Asymptomatic Forms of IgM Monoclonal Gammopathies

Ramón García-Sanz, Roberto JP Magalhaes, Enrique M Ocio, MD, PhD, Pilar Giraldo, MD, PhD, Natalia de las Heras, Carmen Aguilera, Jose Mariano Hernández, Alfonso Garcia de Coca, Noemi Puig, Ilda Murillo, MD, Elena Sebastian, MD, Marcos González, Jesus F. San Miguel, MD, PhD, Norma Gutierrez

Blood (2012) 120 (21): 4566.

https://doi.org/10.1182/blood.V120.21.4566.4566

Published: 2012

Journal Articles

Salvage Treatment with Ofatumumab and ESHAP (O-ESHAP) for Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma After First-Line Chemotherapy: Interim Analysis of a Phase II Trial of the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO)

Carmen Martinez, MD, Mercedes Rodriguez-Calvillo, María José Terol, MD, PhD, Blanca Xicoy, MD, PhD, Ramón García-Sanz, Elena Perez-Ceballos, Alberto Cantalapiedra, Eva Domingo-Domènech, MD, Miguel Hernández, Antonia Sampol, MD, Manuel Espeso, Javier Briones, MD, Javier Lopez, Anna Sureda, MD

Blood (2012) 120 (21): 1630.

https://doi.org/10.1182/blood.V120.21.1630.1630

Published: 2012

Journal Articles

Preferential Acquision of N-Glycosylation Sites in the VDJ Region in Germinal Center B-Cell-Like Difusse Large B-Cell Lymphoma

Miguel Alcoceba, Elena Sebastián, Ana Balanzategui, Luis Marín, Santiago Montes-Moreno, Teresa Flores, Noemí Puig, M. Eugenia Sarasquete, M. Carmen Chillón, Cristina Jiménez, Rocío Corral, Eva González-Barca, M. Dolores Caballero, Jesús F. San Miguel, Ramón García-Sanz, Marcos González

Blood (2012) 120 (21): 1589.

https://doi.org/10.1182/blood.V120.21.1589.1589

Published: 2012

Journal Articles

Intra-Clonal Heterogeneity Is a Critical Early Event in the Preclinical Stages of Multiple Myeloma and Is Subject to Darwinian Fluctuation throughout the Disease

Lorenzo Melchor, PhD, Brian A Walker, BSc, PhD, Christopher P Wardell, PhD, Annamaria Brioli, MD, Martin F Kaiser, MD, Lucía López-Corral, MD, Sean Humphray, Lisa Murray, Mark Ross, David Bentley, Ramón García-Sanz, Jesús F San Miguel, MD, PhD, Faith E. Davies, MD, David Gonzalez, PhD, Gareth J. Morgan, MD PhD

Blood (2012) 120 (21): 3941.

https://doi.org/10.1182/blood.V120.21.3941.3941

Published: 2012

Journal Articles

Relationship Between HLA Class I and II Polymorphisms with Susceptibility and Clinical Outcome in Diffuse Large B-Cell Lymphoma.

Blood (2012) 120 (21): 2680.

https://doi.org/10.1182/blood.V120.21.2680.2680

Published: 2012

Journal Articles

Analysis of Zoledronic ACID Therapy for Patients with Multiple Myeloma with Asymptomatic Biochemical Relaps.

Ramón García-Sanz, Albert Oriol, Javier De La Rubia, MD, Luis Palomera, MD, Paz Ribas, Miguel Teodoro Hernández, Maria José Moreno, Joan Bargay, Angel Ramírez, Ana Isabel Teruel, María Jesús Blanchard, Mercedes Gironella, MD, Miquel Granell, MD, Eugenia Abella, J.F. San Miguel

Blood (2012) 120 (21): 2967.

https://doi.org/10.1182/blood.V120.21.2967.2967

Published: 2012

Journal Articles

Multiparameter Flow Cytometry (MFC) for Identification of the Waldenström's Clone in IgM MGUS and Waldenstrom's Macroglobulinemia (WM): New Criteria for Differential Diagnosis and Risk Stratification

Bruno Paiva, Maria-Carmen Montes, Ramón García-Sanz, Jennifer Alonso, Natalia de las Heras, Fernando Escalante, Alfonso Garcia de Coca, Josefina Galende, Jose Hernández, Alejandro Martín, Emilia Pardal, Abelardo Bárez, Jose M Alonso, MD, Alberto Orfao, Enrique M Ocio, MD, PhD, María-Belén Vidriales, Jesus F. San Miguel, MD, PhD

Blood (2012) 120 (21): 936.

https://doi.org/10.1182/blood.V120.21.936.936

Published: 2012

Journal Articles

Multidimensional Flow Cytometric (MFC) Analysis of the Immune System of Multiple Myeloma (MM) Patients Achieving Long Term Disease Control

Roberto J. Pessoa Magalhaes, María-Belén Vidriales, Bruno Paiva, Maria-Victoria Mateos, Norma C. Gutierrez, Ramón García-Sanz, Juan F Blanco, Jose Hernández, Natalia de las Heras, Joaquin Martinez, MD, Elaine Sobral Costa, MD, PhD, Angelo Maiolino, MD, PhD, M. Nucci, MD, PhD, Javier De La Rubia, Juan-Jose Lahuerta, MD, Alberto Orfao, MD, PhD, Jesús F. San Miguel, Sr., MD, PhD

Blood (2011) 118 (21): 810.

https://doi.org/10.1182/blood.V118.21.810.810

Published: 2011

Journal Articles

Polymorphisms in Regulators of Xenobiotic Transport and Metabolism Genes NR1I2 and NR1I3 and Multiple Myeloma Risk: A Case-Control Study in the Context of IMMEnSE Consortium

Blood (2011) 118 (21): 5014.

https://doi.org/10.1182/blood.V118.21.5014.5014

Published: 2011

Journal Articles

SNP-Based Mapping Arrays Reveal High Genomic Complexity in Monoclonal Gammopathies: From the MGUS to Myeloma Status

Lucía López-Corral, Maria Eugenia Sarasquete, Sílvia Beà, Ramón García-Sanz, Maria Victoria Mateos, Marcos González, MD, Luis Antonio Corchete, Joan Bladé, MD, Albert Oriol-Rocafiguera, Miguel Hernandez, Pilar Giraldo, Jose Hernández, Jesús M Hernández-Rivas, Jesús F San Miguel, Norma C. Gutierrez

Blood (2011) 118 (21): 295.

https://doi.org/10.1182/blood.V118.21.295.295

Published: 2011

Journal Articles

Whole Genome Sequencing Illuminates the Genetic and Biological Features Underlying the Transition of SMM to MM

Brian A Walker, PhD, Christopher P Wardell, PhD, Lucía López-Corral, Sean Humphray, Lisa Murray, Mark Ross, Ramón García-Sanz, David Bentley, Jesús F San Miguel, David Gonzalez, PhD, Gareth J Morgan, MD PhD

Blood (2011) 118 (21): 296.

https://doi.org/10.1182/blood.V118.21.296.296

Published: 2011

Journal Articles

Under Scope of the Current Redefinition Process of Optimal Response in Multiple Myeloma: Assesment of Molecular Response by Fluorescent PCR of Ig Genes Has Similar Applicability and Prognosis Impact to Immunophenotypic Response. (A GEM/PETHEMA study),

Blood (2011) 118 (21): 3951.

https://doi.org/10.1182/blood.V118.21.3951.3951

Published: 2011

Journal Articles

Utility of Multiparameter Flow Cytometry Immunophenotypic Studies In Patients with Systemic Light Chain (AL) Amyloidosis

Bruno Paiva, María-Belén Vidriales, Jose J. Perez, Maria-Consuelo López-Berges, Ramón García-Sanz, Enrique M. Ocio, Rebeca Garcia, Alfonso Garcia de Coca, Emilia Pardal, Magdalena Sierra, Jose Hernández, Natalia de las Heras, Josefina Galende, Jose Maria Alonso, Abelardo Bárez, María-Victoria Mateos, Jesus F San Miguel

Blood (2010) 116 (21): 4051.

https://doi.org/10.1182/blood.V116.21.4051.4051

Published: 2010

Journal Articles

Fluorescence In Situ Hybridization (FISH) Analysis In 160 Patients with IgM Monoclonal Gammopathies

Norma C. Gutierrez, Roberto JP Magalhaes, Ramón García-Sanz, María-Belén Vidriales, Enrique M. Ocio, Bruno Paiva, Daniel del Carpio, Alvaro Caballero, Jennifer Alonso, Lucia Lopez-Anglada, Teresa Villaescusa, Jesus M. Hernandez Rivas, A. Aguilar, Alejandro Martín, R. Lopez, Alberto Orfao, Jesus F San Miguel

Blood (2010) 116 (21): 1916.

https://doi.org/10.1182/blood.V116.21.1916.1916

Published: 2010

Journal Articles

Primary Therapy of Waldenström's Macroglobulinemia (WM) with Weekly Bortezomib, Low-Dose Dexamethasone and Rituximab (BDR): A Phase II Study of the European Myeloma Network

Meletios A. Dimopoulos, Ramón García-Sanz, Maria Gavriatopoulou, Pierre Morel, Marie-Christine Kyrtsonis, Eirini Katodritou, Eurydiki Michalis, Zafiris Kartasis, Xavier Leleu, MD, PhD, Giovanni Palladini, Alessandra Tedeschi, Dimitra Gika, Evangelos Terpos, Giampaolo Merlini, Efstathios Kastritis, Pieter Sonneveld

Blood (2010) 116 (21): 1941.

https://doi.org/10.1182/blood.V116.21.1941.1941

Published: 2010

Journal Articles

Clinical Outcome According to Both Cytogenetic Abnormalities (CA) Detected by Fluorescence In Situ Hibridization (FISH) and Hyperdiploidy Assessed by Flow Cytometry (FCM) In Elderly Newly Diagnosed Myeloma Patients Treated with A Bortezomib-Based Combination

Blood (2010) 116 (21): 309.

https://doi.org/10.1182/blood.V116.21.309.309

Published: 2010

Journal Articles

Identification of Molecular Risk Score in Advanced Hodgkin Lymphoma: Integrating Tumor and Microenvironment Signatures.

Beatriz Sánchez-Espiridión, Carlos Montalbán, Mónica García-Cosio, Jose García-Laraña, Javier Menarguez, Pilar Sabin, Rafael Ramos, José Rodríguez, Francisco Mestre, Miguel Canales, Francisco Javier Alves, Araceli Canovas, Carmen Camarero, Antonio Salar, Sergi Serrano, Angel Castaño, Pedro Sánchez-Godoy, Águeda Bas, Reyes Arranz, Agustín Acevedo, Concepción Rayón, Manuel F. Fresno, Carlos Santonja, Jose Luis López, Manuela Mollejo, Miguel A. Cruz, Hugo Álvarez-Arguelles, Marta LLanos, Carmen Martín, Rafael Martínez, Joaquín González-Carrero, Concepción Poderos, Francisco Mazorra, Eulogio Conde, Teresa Flores, Ramón García-Sanz, Jerónimo Forteza, Máximo Fraga, Jose Luis Bello, María Jose Mestre, Miguel Méndez, Rubén Quibén, Luz Borbolla, Ana Marin-Niebla, Eduardo Ríos, Manuel M. Morente, Miguel A. Piris, Juan F. García

Blood (2009) 114 (22): 3660.

https://doi.org/10.1182/blood.V114.22.3660.3660

Published: 2009

Journal Articles

Final Results of a Phase II Trial with Plitidepsin (Aplidin) Alone and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Maria-Victoria Mateos, Mª Teresa Cibeira, Paul Richardson, Joan Blade, Felipe Prosper, MD, Albert Oriol, Javier de la Rubia, MD, Adrian Alegre, MD, Juan José Lahuerta, MD, PhD, Ramón García-Sanz, MD, PhD, Constantine S. Mitsiades, MD, PhD, Jose Espinoza, MD, Kenneth C. Anderson, J.F. San Miguel

Blood (2008) 112 (11): 3700.

https://doi.org/10.1182/blood.V112.11.3700.3700

Published: 2008

Journal Articles

VAMP/ThaCyDex: Velcade® (Bortezomib), Adriamycin, Melphalan and Prednisone Alternating with Thalidomide, Cyclophosphamide and Dexametasone as a Salvage Regimen in Relapsed Multiple Myeloma Patients

Enrique Colado, MD, Maria-Victoria Mateos, MD, PhD, Maria-Jose Moreno, MD, Felipe de Arriba, MD, Javier de la Rubia, MD, Juan José Lahuerta, MD, PhD, Pastora Iniesta, MD, Maria Cruz Viguria, MD, Ana Pilar Gonzalez, MD, Ramón García-Sanz, MD, PhD, Juan Olazabal, MD, Jesús F San Miguel

Blood (2008) 112 (11): 3694.

https://doi.org/10.1182/blood.V112.11.3694.3694

Published: 2008

Journal Articles

Clinical Prognostic Factors in Chemosensitive Multiple Myeloma (MM) Patients Intensified with High Dose Therapy/Stem Cell Support (HDT/SCS): Results of the Spanish Trial (PETHEMA/GEM2000).

María-Victoria Mateos, MD, PhD, Juán-José Lahuerta, MD, PhD, Anna Sureda, MD, PhD, Javier de la Rubia, MD, PhD, Ramón García-Sanz, MD, PhD, Rafael Martínez, MD, PhD, José García-Laraña, MD, PhD, Felipe de Arriba, MD, PhD, Jose-María Ribera, MD, PhD, Miguel-Teodoro Hernández, MD, PhD, Lourdes Escoda, MD, PhD, Dolores Carrera, MD, PhD, Joan Besalduch, MD, PhD, B. Hernández, MD, PhD, P. Fernández, MD, PhD, Joan Blade, MD, PhD, J.F. San Miguel, MD, PhD

Blood (2007) 110 (11): 937.

https://doi.org/10.1182/blood.V110.11.937.937

Published: 2007

NARROW

6q Deletion Helps in the Discrimination Between Symptomatic Waldenström's Macroglobulinemia and Asymptomatic Forms of IgM Monoclonal Gammopathies

Salvage Treatment with Ofatumumab and ESHAP (O-ESHAP) for Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma After First-Line Chemotherapy: Interim Analysis of a Phase II Trial of the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO)

Preferential Acquision of N-Glycosylation Sites in the VDJ Region in Germinal Center B-Cell-Like Difusse Large B-Cell Lymphoma

Intra-Clonal Heterogeneity Is a Critical Early Event in the Preclinical Stages of Multiple Myeloma and Is Subject to Darwinian Fluctuation throughout the Disease

Relationship Between HLA Class I and II Polymorphisms with Susceptibility and Clinical Outcome in Diffuse Large B-Cell Lymphoma.

Analysis of Zoledronic ACID Therapy for Patients with Multiple Myeloma with Asymptomatic Biochemical Relaps.

Multiparameter Flow Cytometry (MFC) for Identification of the Waldenström's Clone in IgM MGUS and Waldenstrom's Macroglobulinemia (WM): New Criteria for Differential Diagnosis and Risk Stratification

Multidimensional Flow Cytometric (MFC) Analysis of the Immune System of Multiple Myeloma (MM) Patients Achieving Long Term Disease Control

Polymorphisms in Regulators of Xenobiotic Transport and Metabolism Genes NR1I2 and NR1I3 and Multiple Myeloma Risk: A Case-Control Study in the Context of IMMEnSE Consortium

SNP-Based Mapping Arrays Reveal High Genomic Complexity in Monoclonal Gammopathies: From the MGUS to Myeloma Status

Whole Genome Sequencing Illuminates the Genetic and Biological Features Underlying the Transition of SMM to MM

Under Scope of the Current Redefinition Process of Optimal Response in Multiple Myeloma: Assesment of Molecular Response by Fluorescent PCR of Ig Genes Has Similar Applicability and Prognosis Impact to Immunophenotypic Response. (A GEM/PETHEMA study),

Utility of Multiparameter Flow Cytometry Immunophenotypic Studies In Patients with Systemic Light Chain (AL) Amyloidosis

Fluorescence In Situ Hybridization (FISH) Analysis In 160 Patients with IgM Monoclonal Gammopathies

Primary Therapy of Waldenström's Macroglobulinemia (WM) with Weekly Bortezomib, Low-Dose Dexamethasone and Rituximab (BDR): A Phase II Study of the European Myeloma Network

Clinical Outcome According to Both Cytogenetic Abnormalities (CA) Detected by Fluorescence In Situ Hibridization (FISH) and Hyperdiploidy Assessed by Flow Cytometry (FCM) In Elderly Newly Diagnosed Myeloma Patients Treated with A Bortezomib-Based Combination

Identification of Molecular Risk Score in Advanced Hodgkin Lymphoma: Integrating Tumor and Microenvironment Signatures.

Final Results of a Phase II Trial with Plitidepsin (Aplidin) Alone and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

VAMP/ThaCyDex: Velcade® (Bortezomib), Adriamycin, Melphalan and Prednisone Alternating with Thalidomide, Cyclophosphamide and Dexametasone as a Salvage Regimen in Relapsed Multiple Myeloma Patients

Clinical Prognostic Factors in Chemosensitive Multiple Myeloma (MM) Patients Intensified with High Dose Therapy/Stem Cell Support (HDT/SCS): Results of the Spanish Trial (PETHEMA/GEM2000).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only